Lab
DB Labs LLC
DB Labs LLC was paid $3.10M by Medicaid between Jan 2018 and Nov 2024, across 59 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 27% of everything it billed.
33Billing provider infoDB LABS LLC
MADISON HEIGHTS, MI 48071
MADISON HEIGHTS, MI 48071
33aNPI1760858641assigned 08/14/2015
33bProvider typeClinical Medical Laboratory
28Total paid$3.10M
24GClaims46,642
24DCodes billed59
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Michigan
Rank by total paid#20 of 108
Median peer was paid$588K
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 185 | $16K | |
| 2019 | 10,966 | $487K | |
| 2020 | 2,370 | $119K | |
| 2021 | 1,202 | $49K | |
| 2022 | 12,340 | $765K | |
| 2023 | 10,488 | $748K | |
| 2024incomplete | 9,091 | $913K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 27% | 9,397 | 8,506 | $838K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 26% | 9,031 | 8,218 | $802K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 17% | 6,670 | 6,100 | $523K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 17% | 6,147 | 4,778 | $519K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.0% | 3,934 | 3,127 | $218K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.1% | 3,405 | 2,662 | $64K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 2,207 | 1,275 | $41K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 92 | 92 | $25K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 759 | 620 | $13K |
| 87481 | <1% | 77 | 77 | $8K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 375 | 372 | $4K |
| 80061 | Lipid panel | <1% | 496 | 494 | $4K |
47 more codes
| 87653 | <1% | 106 | $3K | |
| 80053 | Comprehensive metabolic panel | <1% | 436 | $2K |
| 87529 | <1% | 46 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 271 | $2K |
| 80074 | <1% | 55 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 78 | $2K |
| 87640 | <1% | 64 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 62 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 60 | $1K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 391 | $1K |
| 82607 | <1% | 228 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 78 | $1K |
| 87511 | <1% | 57 | $1K | |
| 83037 | <1% | 250 | $1K | |
| 82746 | <1% | 96 | $909.26 | |
| 86803 | <1% | 107 | $896.87 | |
| 82728 | <1% | 96 | $822.14 | |
| 84439 | <1% | 225 | $798.10 | |
| 86708 | <1% | 106 | $758.89 | |
| 87340 | <1% | 107 | $753.01 | |
| 86709 | <1% | 107 | $698.77 | |
| 86706 | <1% | 106 | $683.21 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 26 | $634.17 |
| 86800 | <1% | 58 | $633.62 | |
| 87641 | <1% | 28 | $620.52 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 135 | $575.25 |
| 84481 | <1% | 45 | $488.16 | |
| 83970 | <1% | 15 | $475.18 | |
| 87563 | <1% | 27 | $464.36 | |
| 84480 | <1% | 108 | $455.70 | |
| 82248 | <1% | 87 | $326.15 | |
| 82670 | <1% | 13 | $278.98 | |
| 84403 | <1% | 14 | $277.34 | |
| 84402 | <1% | 14 | $273.68 | |
| 84144 | <1% | 14 | $224.10 | |
| 82627 | <1% | 13 | $221.93 | |
| 83001 | <1% | 14 | $199.59 | |
| 83002 | <1% | 14 | $199.16 | |
| 84153 | <1% | 13 | $182.39 | |
| 82533 | <1% | 14 | $175.22 | |
| 85045 | <1% | 70 | $172.80 | |
| 84100 | <1% | 18 | $110.67 | |
| 83540 | <1% | 17 | $84.23 | |
| 83735 | <1% | 15 | $77.09 | |
| 81001 | <1% | 16 | $46.91 | |
| 84436 | <1% | 16 | $3.79 | |
| 80050 | General health panel | 0% | 116 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIGLER, YISROEL (MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Clinical Connect Laboratories, LLC | Madison Heights, MI | $3.83M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.